checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
Published 2 years ago • 205 plays • Length 5:22Download video MP4
Download video MP3
Similar videos
-
2:06
nivolumab plus ipilimumab vs chemotherapy in unresectable mesothelioma
-
4:05
checkmate 9la: first-line nivolumab ipilimumab 2 cycles chemotherapy vs 4 cycles chemo in an...
-
3:48
nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
9:32
checkmate 648: nivolumab plus ipilimumab or nivo plus chemo versus chemo as (1l) treatment for a...
-
2:00
checkmate 8hw: first-line nivolumab plus ipilimumab in msi-h/dmmr mcrc
-
2:06
checkmate-743 study in mesothelioma
-
5:43
checkmate 9la trial on nivolumab plus ipilimumab for nsclc
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
3:49
nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hcc
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
2:02
hrqol findings from checkmate 8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
3:43
latest from checkmate 650: nivolumab plus ipilimumab for the treatment of metastatic castration-...
-
7:50
keynote-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic nsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
7:47
nivolumab/ipilimumab approved in europe for frontline unresectable malignant pleural mesothelioma
-
1:19
29-month follow-up from checkmate 648: nivolumab combination therapy in escc